Noul, a Korean medtech firm specializing in artificial intelligence (AI)-driven diagnostic tools, has entered the Indonesian market through its first supply agreement for an automated cervical cancer screening system as the Southeast Asian nation works to scale up preventive care. The company said Thursday it signed the agreement with an Indonesian medical device distributor and plans to supply at least 50 miLab CER units to local medical institutions and laboratory networks over three years. Noul said it will initially work with hospitals, screening centers and laboratory networks before seeking opportunities in Indonesia’s public procurement market. The company said it has secured regulatory approvals for miLab CER in several Southeast Asian markets, including Vietnam and the Philippines, providing a foundation for further expansion across the region. Indonesia, with about 280 million people, is Southeast Asia’s largest health care market, according to Noul, which said cervical cancer places a significant burden on women in the country. Noul said Indonesia plans to include cervical
Will Philippines win race to secure Pax Silica hub before neighbours do?